An Open-Label Phase 2 Safety and Efficacy Study of EPI-743 (Vincerinone) in Children With Pearson Syndrome.
Phase of Trial: Phase II
Latest Information Update: 23 Mar 2016
At a glance
- Drugs Vatiquinone (Primary)
- Indications Mitochondrial disorders
- Focus Therapeutic Use
- Sponsors Edison Pharmaceuticals
- 23 Nov 2015 Status changed from active, no longer recruiting to discontinued, as reported by ClinicalTrials.gov.
- 21 Aug 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 20 Aug 2014 Planned End Date changed from 1 May 2016 to 1 Apr 2016 as reported by ClinicalTrials.gov.